Device Trial Radar · NCT06071429
Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Apr 11, 2025
Primary completion
Mar 1, 2028
Study completion Mar 1, 2032
Sponsor
- Lead sponsor
- R3 Vascular Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 6, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this prospective, single-blinded, randomized controlled trial is to evaluate the safety and efficacy of the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Approximately 276 subjects will be randomized in a 1:1 ratio. The clinical investigation will be conducted at up to 60 clinical sites globally.
Conditions
- Chronic Limb-Threatening Ischemia
Interventions
MAGNITUDE Sirolimus-eluting Bioresorbable ScaffoldDevice
CLTI patients treated with MAGNITUDE BRS
Percutaneous Transluminal Angioplasty (PTA)Device
CLTI patients treated with PTA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Safety Endpoint: Freedom from MALE+POD (Major Adverse Limb Event + Peri-Operative Death)Time frame: POD at 30 Days and MALE at 6 months
1 more outcomes with a free account
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York · Recruiting
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.